BWAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Brainsway Ltd (BWAY) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong financial growth, positive analyst sentiment, and a promising product pipeline, making it a solid choice for long-term holding.
The MACD is below 0 and negatively contracting, indicating a bearish trend, while the RSI is neutral at 47.349. The stock is trading near its pivot level of 22.662, with key resistance at 24.442 and support at 20.881. Moving averages are converging, suggesting indecision in the market.
Analysts have raised the price target to $30 from $24, citing strategic partnerships and FDA-approved protocols.
Recent financial performance shows significant growth in revenue (+28.66% YoY), net income (+136.56% YoY), and EPS (+100% YoY).
The company received premarket approval for Neurolief's Proliv RX system, which could drive future growth.
The stock has a 50% chance of declining slightly (-1.37%) in the next week.
Technical indicators suggest a lack of strong upward momentum currently.
In Q3 2025, Brainsway reported revenue growth of 28.66% YoY, net income growth of 136.56% YoY, and EPS growth of 100% YoY. Gross margin also improved to 75.19%, up 2.27% YoY, reflecting strong operational efficiency.
Analysts are bullish on the stock, with H.C. Wainwright and Northland raising their price targets to $30 and maintaining Buy/Outperform ratings. They highlight the company's FDA-approved protocols, strategic partnerships, and product pipeline as key drivers of growth.
